Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Yili introduces 'dual centers' and 'dual integration' strategy at the Global Dairy Congress 2021-06-25 17:57
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 2021-06-25 15:11
Made-in-China.com targets trade in multiple languages beyond English 2021-06-25 13:21
Shanghai Disney Resort and DEI Announce Multi-Year Resort Alliance 2021-06-25 13:13
JA Solar Signs 2021 Cooperation Agreement with Mexican PV Distributor Exel Solar 2021-06-25 12:47
CNOOC Limited Announces The China's First Offshore Large-sized Independent Deepwater Gas Field Lingshui 17-2 Gas Field Commences Production 2021-06-25 12:08
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions 2021-06-25 08:00
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE 2021-06-25 00:26
TCP Group Unveils New Red Bull Ambassador in China - Yi Jianlian and Officially Launches the 2021 "Ni Zhen Niu Hong Niu Ting Ni" Marketing Campaign 2021-06-24 23:06
Absen wins the U.S. Ultravision Intellectual Property Case 2021-06-24 20:48
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan 2021-06-24 19:00
Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness® VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds 2021-06-24 18:00
China's first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876) 2021-06-24 14:46
Qionglai establishes cooperative ties with Tajimi in Japan 2021-06-24 09:56
The investor who incorporates altruism into the business model 2021-06-24 09:48
CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application 2021-06-24 08:05
CEO of Kuaishou Su Hua: Kuaishou reaches 1 billion global monthly active users 2021-06-24 02:29
CGTN: Chinese astronauts' talk with Earth from space 2021-06-24 01:30
Ping An Chairman Marks 33rd Anniversary of Group with Message: My Thoughts on the New Digitalization 2021-06-23 20:02
Yili Remains China's Most Chosen Brand, Reaching over 90% of Households for Six Consecutive Years 2021-06-23 19:38
1 566 567 568 569 570 1210